Sun Pharma to Acquire Organon for $11.75 Billion

On April 26, 2026, Sun Pharmaceutical Industries (Sun Pharma) announced an agreement to acquire Organon & Co. in an all-cash transaction valued at $14.00 per share, an enterprise value of approximately $11.75 billion including the assumption of Organon's existing debt. The transaction, India's largest outbound pharmaceutical acquisition to date, is also the closing chapter of the company that Merck spun out only five years earlier as a standalone women's health and biosimilars business. For owners and boards, the structure of the deal illustrates how cross-border buyers price targets that carry meaningful leverage, and why the spin-off-then-sale pattern continues to recur even when the original spin was executed for sound strategic reasons.

What Was Announced

Sun Pharma will pay $14.00 per share in cash for all outstanding equity of Organon, a price the parties reported as a 27 percent premium to the volume-weighted average trading price over the prior month. Organon's stock rose roughly 17 percent on the announcement; Sun Pharma's stock rose 7 percent. The total enterprise value of $11.75 billion includes the assumption of Organon's net debt, which sits at approximately $8.6 billion against $574 million of cash, a net-debt-to-EBITDA ratio of roughly 4x at the trailing run rate.

The transaction is expected to close in early 2027, subject to Organon shareholder approval, U.S. and foreign antitrust clearance, and a number of customary closing conditions. On a combined basis, Sun Pharma's revenue will rise to approximately $12.4 billion, placing the buyer among the top 25 global pharmaceutical companies and giving it significant standing in women's health and biosimilars, two categories where Sun Pharma had limited presence before the transaction.

The Spin-Off-to-Sale Lifecycle

Merck spun out Organon in 2021 with a mandate to focus on a portfolio of mature women's health products, biosimilars, and a set of established brand pharmaceuticals that no longer fit Merck's research-driven strategy. At the time, the spin was a textbook example of conglomerate simplification: the parent retained its high-growth oncology and vaccines focus, while the spin-off carried the cash-generative but slower-growing assets along with a substantial slice of the parent's debt.

The Sun Pharma transaction is the predictable next step in that lifecycle. Spin-offs of mature product portfolios often face two pressures over time. The first is investor patience. Spin-off equities are typically held by a different shareholder base than their parents, and that base loses interest if the standalone narrative does not materialize. The second is leverage discipline. A spin-off that inherits parental debt has limited room to invest in new product development, and free cash flow tends to be directed toward debt service rather than growth. Within five years of separation, the practical options narrow to refinancing, divestiture of the highest-quality assets, or a sale of the entire entity.

Sun Pharma's logic is that the products that defined Organon's spin-off, contraceptives, hormone therapies, and biosimilars, are precisely the products that fit a global buyer with cost-advantaged manufacturing and a strong emerging-markets distribution network. What was a strategic mismatch for Merck and a slow-growth standalone for public market investors can be a high-margin, scaled platform for the right strategic acquirer.

Pricing a Debt-Laden Target

The transaction is also a useful study in how sophisticated buyers price targets that carry significant leverage. The headline equity premium of 27 percent looks generous in isolation, but the relevant question for buyers and sellers is the implied multiple on enterprise value, not on equity. At an enterprise value of $11.75 billion against trailing-twelve-month EBITDA of roughly $1.8 billion, Sun Pharma is paying approximately 6.5x EV/EBITDA. That is a meaningful discount to current public-market pharmaceutical multiples, which sit closer to 11x for diversified specialty platforms.

The discount reflects three real risks the buyer is absorbing. First, the assumed debt has covenants and refinancing milestones that constrain integration choices. Second, several of Organon's largest products face patent step-downs and biosimilar competition over the medium term, which compresses the EBITDA bridge in the model. Third, cross-border integration of a U.S.-listed target into an India-headquartered acquirer involves regulatory, tax, and operational complexity that strategic acquirers have historically priced into their bids.

For owners of debt-laden businesses contemplating a sale, the practical lesson is that the EBITDA multiple is the cleaner negotiation reference, not the equity premium. Equity premia on highly levered targets can look generous and still leave the seller short of a fair enterprise value. Sellers should insist on transparent enterprise value modeling, with explicit treatment of assumed debt, transaction costs, working capital pegs, and any cash deemed required at close.

Why Cross-Border Pharmaceutical M&A Is Accelerating

The Sun Pharma transaction sits within a broader pattern. Indian pharmaceutical companies, long oriented around generics, have begun to make larger, more strategic outbound acquisitions to diversify into specialty, biosimilars, and consumer health. Aurobindo's 2025 acquisition of Lannett for approximately $250 million was an early signal. The Sun Pharma deal is roughly forty-five times that scale and signals that the largest Indian players intend to compete with European and U.S. specialty platforms on global terms, not regional ones.

Several conditions are converging to make this possible. Indian pharmaceutical companies have generated substantial cash from generics over the last decade and now have access to international debt markets at competitive rates. U.S. and European pharmaceutical platforms with mature product portfolios have become more available as their parents simplify and as financial sponsors look to exit positions taken when interest rates were lower. The currency cost of an outbound acquisition is offset, in part, by the dollar-denominated revenue the acquired business generates.

For owners of mature U.S. specialty pharmaceutical businesses, the implication is direct. The buyer universe has expanded. A sale process designed only around domestic strategic acquirers and U.S.-based financial sponsors is leaving value on the table. Cross-border buyers should be invited into early diligence and given enough information to size their bids competitively.

Practical Considerations for Sellers Considering a Spin-Then-Sale Path

A significant share of mid-cap and large-cap public companies will face the same portfolio question that Merck faced in 2021: whether the right path for a non-core segment is a spin-off, a sale, or a continued internal investment program. The Organon arc offers a few practical observations.

A spin-off is a defensible answer when the segment has a credible standalone equity story, an investor base that can be assembled in advance through targeted communications, and a capital structure that gives management room to invest. A spin-off is a difficult answer when the segment is mature, the parent must transfer significant debt to balance the transaction, and the segment's products face known patent or biosimilar exposures. In the latter case, a direct sale to a strategic acquirer often delivers higher value, even net of the loss of optionality.

For owners of private companies with similar characteristics (a mature, cash-generative segment that no longer fits the strategic core), the path forward is rarely a public spin-off but is often a carve-out sale to a strategic acquirer or a financial sponsor. The valuation logic is the same: pure-play buyers who can underwrite the segment on its own economics will typically outbid diversified buyers who must defend the cross-subsidies.